Ultragenyx Pharmaceutical is under investigation by Pomerantz LLP for potential securities fraud following the company's announcement that its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet primary and key secondary endpoints. This news led to a sharp 44.03% drop in Ultragenyx's stock price. The investigation aims to determine if Ultragenyx and its officers engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for possible class action participation.
Ultragenyx Pharmaceutical is the subject of an investigation following its recent clinical trial results. For readers following the Health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: out of 91 priced US Health stocks, 59 rose and 31 fell. Notable moves include CTXR at USD 0.58 with a 4.20% increase and 100% buy order activity, XRAY at USD 9.77 down 3.65%, and ASND at USD 238.79 down 3.59% with 91% sell order activity.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
